文献速递临床试验与 GCP流行病学与生物统计

低成本应用DIALOG+干预门诊焦虑抑郁的多中心实用集群随机对照试验

Low cost app-based intervention DIALOG+ for anxiety and depression in outpatient psychiatric settings: a pragmatic multisite cluster randomized controlled trial.
PubMed 文献 · Trials · 2026-08-01

该试验在印度金奈和本地治里四个精神科门诊开展,拟纳入18-65岁焦虑和/或抑郁障碍成人,随机接受DIALOG+联合常规治疗或DIALOG量表联合常规治疗,评估6个月内生活质量(MANSA)变化及抑郁焦虑症状、可行性与可接受性。

要点

  • DIALOG+为低成本应用式解决方案聚焦干预,此前已在精神病性障碍等慢性精神疾病中验证。
  • 主要结局为MANSA评估的生活质量改善,次要结局包括DASS-21、HDRS和HAM-A。
  • 可行性通过招募、保留和干预保真率评估,可接受性通过参与者和临床医生访谈探索。

研究设计与样本

  • 多中心实用集群随机对照试验,在印度金奈和本地治里四个精神科门诊开展。
  • 纳入18-65岁焦虑和/或抑郁障碍成人,随机分配至DIALOG+联合常规治疗组或DIALOG量表联合常规治疗组。
  • 干预周期6个月,随访评估在3个月和6个月进行,分析采用意向性治疗原则。

关键数值与推荐

  • 主要结局为MANSA评估的生活质量改善。
  • 次要结局包括DASS-21、HDRS和HAM-A评估的抑郁和焦虑变化。
  • 可行性评估指标为招募率、保留率和干预保真率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinically diagnosed anxiety and depressive disorders are widely recognized as the most common mental health issues in India, affecting approximately 15% of the population. With notable gender disparities, Tamil Nadu has some of the highest depression rates in the nation. Despite the growing burden, countries such as India that fall within the low and middle-income countries (LMICs) continue to struggle with mental health services due to challenges in funding, a lack of qualified practitioners, and obstacles to putting evidence-based treatments like Cognitive Behaviour Therapy (CBT) into practice. Innovative, low-cost, and scalable approaches are required to address this gap. This multisite pragmatic randomized controlled trial (RCT) seeks to assess the feasibility, acceptability, and evaluate the effectiveness of DIALOG+ , a low-cost app-based solution-focused intervention designed to enhance quality of life and reduce mental distress. While previously validated for psychosis and other chronic psychiatric conditions, this study aims to evaluate its potential for individuals with anxiety and depression in outpatient psychiatric services in India. METHODS: A pragmatic multisite randomized controlled trial will be conducted across four outpatient psychiatric settings in Chennai and Puducherry to assess the feasibility, acceptability, and effectiveness of DIALOG+, a low-cost app-based intervention. Adults (18-65 years) with anxiety and/or depressive disorders will be randomly allocated to receive either DIALOG+ together with treatment as usual (TAU) or the DIALOG Scale alongside treatment as usual (TAU) over a 6-month period. The key outcome of this study is the improvement in quality of life, evaluated using the Manchester Short Assessment of Quality of Life (MANSA). Secondary outcomes will include changes in depression and anxiety measured using the Depression, Anxiety, and Stress Scale (DASS-21), Hamilton Depression Rating Scale (HDRS), and Hamilton Anxiety Rating Scale (HAM-A). Feasibility will be assessed through recruitment, retention, and intervention fidelity rates, and acceptability will be explored through interviews with participants and clinicians. Assessments at follow-up will be carried out at 3 and 6 months, and analyses will be performed using an intention-to-treat approach. DISCUSSION: If feasible, acceptable, and effective, DIALOG+ for clinically diagnosed persons with anxiety and depressive disorders could represent a transformative, scalable solution for improving mental health outcomes in India and similar LMIC contexts. TRIAL REGISTRATION: The study is registered with the Clinical Trial Registry-India (CTRI), and the registration number is CTRI/2025/08/092477. The registration was done on August 6, 2025.The URL of the trial registry record is https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=133110&EncHid=16149.91763&modid=1&compid=19 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Juliet HO, Davis S, Kantipudi SJ, et al. Low cost app-based intervention DIALOG+ for anxiety and depression in outpatient psychiatric settings: a pragmatic multisite cluster randomized controlled trial. Trials. 2026. PMID: 42947175. doi:10.1186/s13063-026-09871-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。